COMMUNIQUÉS West-GlobeNewswire

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
24/07/2025
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, [...]
The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results
24/07/2025
SCOTTSDALE, Ariz., July 24, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its second [...]
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
24/07/2025
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading [...]
Cannara Secures 5 Key Listings in Québec’s New Vape Cartridge Category Including to be Released Live Rosin Vapes
24/07/2025
MONTREAL, July 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara obtient 5 inscriptions clés dans la nouvelle catégorie de cartouches de vapotage de la SQDC, y compris des cartouches de vapotage à base de rosine vivante à venir
24/07/2025
MONTRÉAL, 24 juill. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » , « la Société » , « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
24/07/2025
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based [...]
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will [...]
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
24/07/2025
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial [...]
Microbix Exhibiting & Presenting at ADLM
24/07/2025
Microbix & API Presenting H5N1 Pandemic Preparedness Results MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]
Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck
24/07/2025
Breckenridge Distillery Unveils Casa Breck: An Artisanal Tequila inspired by the rich traditions of Jalisco and the adventurous spirit of the Rockies BRECKENRIDGE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Breckenridge [...]
TCG Labs Soleil Raises an Additional $400 Million and Expands Global R&D Capabilities
24/07/2025
SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R&D hub, today announced that it has raised an additional $400 million. This [...]
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
24/07/2025
Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be [...]
Biomea Fusion Appoints Julianne Averill to its Board of Directors
24/07/2025
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the [...]
Javvy Protein Coffee Officially Launches, Redefining Javy Coffee Protein United States & Canada
24/07/2025
Javvy Protein Coffee launches in the United States and Canada, blending clean protein with premium coffee to fuel your day with energy, focus, and flavor. New York City, NY, July 24, 2025 (GLOBE NEWSWIRE) -- A new era [...]
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
24/07/2025
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- [...]
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients
24/07/2025
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/ [...]
Communiqué de presse : Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026
24/07/2025
Efluelda ® , le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026 Paris, le 24 juillet 2025 – Sanofi annonce la mise à disposition en France d'Efluelda, son vaccin haute [...]
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
24/07/2025
Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion) Regulatory submissions underway for zongertinib and nerandomilast, with launches expected [...]

Pages